ATP and Biolojic Design Launch Aulos Bioscience to Develop Highly Differentiated IL-2 Antibody Approach to Fighting Cancer | Antibodies
Hits: 772 Aulos Bioscience to Present at the 39th Annual J.P. Morgan Healthcare Conference BOSTON, MA, USA and TEL AVIV, Israel I January 8, 2021 I ATP, a leading life sciences venture capital firm, and Biolojic Design, a biotechnology company that computationally designs functional antibodies, today unveiled Aulos Bioscience, a new company that is developing highly differentiated interleukin-2 (IL-2)-binding monoclonal antibodies as therapeutics against solid tumors. ATP has committed $40 million in Series A funding to advance Aulos' lead molecule from preclinical stage through clinica...
Source: pipelinereview.com